Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Amitiza

Eli Lilly HQ

Lilly’s Lantus ‘follow-on’ approved in the US

Basaglar is first insulin product to be licensed via the FDA's truncated 505(b)(2) pathway

- PMLiVE

NICE backs Xtandi but turns down Zytiga

Astellas and Medivation's pre-chemotherapy prostate cancer drug receives support

- PMLiVE

NICE changes stance on AZ’s Lynparza after concessions

NHS patients in England and Wales to get ovarian cancer drug

Eli Lilly HQ

Lilly says insulin peglispro too risky to pursue

Discontinues development of medicine once tipped as a diabetes blockbuster

- PMLiVE

Blue Latitude’s industry-first praised at PMEA

Support for Lilly and its Medical Information Cascade wins Innovation Award

- PMLiVE

Alexion’s rare bone disorder therapy rejected by NICE

Draft guidance rules Strensiq does not have a compelling enough evidence base

National Institute for Health and Care Excellence NICE logo

NICE recommends two drugs for ovarian cancer but rejects three

Paclitaxel and Caelyx given preliminary nod

Eli Lilly HQ

FDA clears Lilly’s lung cancer drug Portrazza

First biologic drug to be approved as first-line therapy for NSCLC

National Institute for Health and Care Excellence NICE logo

BioMarin’s real world data sways NICE on orphan drug Vimizim

Rare genetic disorder treatment recommended in final draft guidance

- PMLiVE

Cancer Drugs Fund overhaul promises faster access to drugs

Proposals suggest turning CDF into 'managed access' fund

- PMLiVE

Repatha’s price tag too rich for UK’s NICE

HTAbody turns the cholesterol-lowering antibody down in draft guidance

Eli Lilly HQ

Sanofi and Lilly highlight rheumatoid arthritis hopefuls at ACR

Top-line results for sarilumab and baricitinib

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links